Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Grows By 71.6%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 182,800 shares, a growth of 71.6% from the February 13th total of 106,500 shares. Based on an average daily volume of 2,260,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 2.2% of the shares of the stock are short sold.

Insider Activity at Cyclacel Pharmaceuticals

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total value of $5,838,864.60. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 23.97% of the stock is owned by corporate insiders.

Cyclacel Pharmaceuticals Price Performance

NASDAQ:CYCC opened at $0.30 on Monday. The company has a market cap of $1.87 million, a price-to-earnings ratio of -0.03 and a beta of 0.28. The stock’s 50 day simple moving average is $0.35 and its two-hundred day simple moving average is $0.57. Cyclacel Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $4.00.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research note on Saturday. They issued a “sell” rating on the stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.